The Effectiveness of Molecular Assays and Sampling Methods: An Application on HPV Detection in Oropharyngeal and Oral Cavity Cancers

2.50
Hdl Handle:
http://hdl.handle.net/10755/601823
Category:
Full-text
Format:
Text-based Document
Type:
Presentation
Title:
The Effectiveness of Molecular Assays and Sampling Methods: An Application on HPV Detection in Oropharyngeal and Oral Cavity Cancers
Other Titles:
Working with Families to Improve Clinical Outcomes [Session]
Author(s):
Kostas-Polston, Elizabeth A.
Lead Author STTI Affiliation:
Tau Theta
Author Details:
Elizabeth A. Kostas-Polston, APRN, WHNP-BC, FAANP, epolston@slu.edu
Abstract:
Session presented on Friday, July 24, 2015: Purpose: In recent years, the oropharyngeal (OP) squamous cell carcinoma (SCC) demographic has changed drastically.' While OPSCC once afflicted older men who were heavy smokers and drinkers, the new generation of OPSCC patient tends to be a younger affluent male who is a non-smoker and non-drinker, with more sexual partners, greater oral sex exposure, and an HPV positive tumor.' Currently, there are no FDA approved screening tests for the detection of HPV infections specifically targeting the oropharynx.' This study aims to a) identify differences in the sensitivity and specificity across molecular and cytological assays and sampling methods, and b) explore how well molecular and cytological assays predict the presence of HPV infection of the oropharynx.''' ' Methods: Using a cross-sectional design, this exploratory pilot study involved 41 individuals with a sore, irritation, lump, and/or thick, red or white patch in their mouth or on their tonsils, who presented to a Midwestern Head & Neck clinic.' Informed consent was valid for collection of: 1) data from the Sexual History and Social Behavior Survey, 2) exfoliated cells from the lesion, 3) saliva samples, and 4) tissue (routine biopsy).' The analytic methods explored included Hologic CervistaTM HR HPV Test (Third Wave Invader Chemistry-DNA') and cytology.' The two sampling methods explored included the Non-GYN Thin Prep'3 and Oragene''DNA Saliva containers.' Analytic and sampling methods and biological samples were tested in various combinations and compared to the gold standard (biopsy tissue): 1) histology for clinical diagnosis, 2) DNA analysis for HR HPV status, and 3) p16 immunohistochemistry (IHC) staining (a biomarker of HPV infection) (Please refer to Table 1).'' '' Results: The sensitivities for the Oragene-Saliva-CervistaHR, ThinPrep-Saliva-CervistaHR, ThinPrep-Scraping-CervistaHR, and ThinPrep-Scraping-Cytology were 100%, 50%, 73.68%, and 36.84%, in order, and their respective specificities were 23.81%, 66.67%, 80.95%, and 71.43%.' There were no statistically significant differences between their performance when testing oropharyngeal and oral cavity lesions (p > 0.05). Conclusion: The high sensitivity (100%) and low specificity (23.81) of Oragene-Saliva-CervistaHR shows that it has a tendency to produce a large number of false positive results.' Since biopsy diagnosis is both expensive and invasive, a test like the ThinPrep-Scraping-CervistaHR with a more balanced sensitivity (73.68%) and specificity (80.95%) is preferred.' Of the four combinations tested, we recommend further investigation of the ThinPrep-Scraping-CervistaHR test.' If proven to be effective, this mildly invasive, readily available, and cost effective method can promote early detection and improve prognosis for the new generation of OPSCC patients. TABLE 1.' METHODS'' Sexual History & Social'' ' Behavior Questionnaire' ' Demographic & Descriptives ''' Saliva, Exfoliated Cells ' and Biopsy Tissue ' 1.' Gold Standard '' Biopsy tissue Histology:' Routine Evaluation & DiagnosisDNA Analysis for HR HPV Statusp16 IHC Staining for HPV Detection' 2.' Combinations (Biologic Sample, Collection Container, and Assay HPV Positive & Negative Saliva and Exfoliated Cells Oragene'-DNA/Saliva Container AND CytologyOragene'-DNA/Saliva Container AND Hologic Cervista' HR HPV Test (Third Wave Invader Chemistry-DNA')Non-GYN ThinPrep' Liquid Based Container/Saliva AND CytologyNon-GYN ThinPrep' Liquid Based Container /Saliva AND Hologic Cervista' HR HPV Test (Third Wave Invader Chemistry-DNA')
Keywords:
HPV-Related Oropharyngeal Cancer; Human Pepillomavirus; Screening
Repository Posting Date:
17-Mar-2016
Date of Publication:
17-Mar-2016 ; 17-Mar-2016
Other Identifiers:
INRC15D08
Conference Date:
2015
Conference Name:
26th International Nursing Research Congress
Conference Host:
Sigma Theta Tau International, the Honor Society of Nursing
Conference Location:
San Juan, Puerto Rico
Description:
Research Congress 2015 Theme: Question Locally, Engage Regionally, Apply Globally. Held at the Puerto Rico Convention Center.

Full metadata record

DC FieldValue Language
dc.language.isoenen
dc.type.categoryFull-texten
dc.formatText-based Documenten
dc.typePresentationen
dc.titleThe Effectiveness of Molecular Assays and Sampling Methods: An Application on HPV Detection in Oropharyngeal and Oral Cavity Cancersen
dc.title.alternativeWorking with Families to Improve Clinical Outcomes [Session]en
dc.contributor.authorKostas-Polston, Elizabeth A.en
dc.contributor.departmentTau Thetaen
dc.author.detailsElizabeth A. Kostas-Polston, APRN, WHNP-BC, FAANP, epolston@slu.eduen
dc.identifier.urihttp://hdl.handle.net/10755/601823-
dc.description.abstractSession presented on Friday, July 24, 2015: Purpose: In recent years, the oropharyngeal (OP) squamous cell carcinoma (SCC) demographic has changed drastically.' While OPSCC once afflicted older men who were heavy smokers and drinkers, the new generation of OPSCC patient tends to be a younger affluent male who is a non-smoker and non-drinker, with more sexual partners, greater oral sex exposure, and an HPV positive tumor.' Currently, there are no FDA approved screening tests for the detection of HPV infections specifically targeting the oropharynx.' This study aims to a) identify differences in the sensitivity and specificity across molecular and cytological assays and sampling methods, and b) explore how well molecular and cytological assays predict the presence of HPV infection of the oropharynx.''' ' Methods: Using a cross-sectional design, this exploratory pilot study involved 41 individuals with a sore, irritation, lump, and/or thick, red or white patch in their mouth or on their tonsils, who presented to a Midwestern Head & Neck clinic.' Informed consent was valid for collection of: 1) data from the Sexual History and Social Behavior Survey, 2) exfoliated cells from the lesion, 3) saliva samples, and 4) tissue (routine biopsy).' The analytic methods explored included Hologic CervistaTM HR HPV Test (Third Wave Invader Chemistry-DNA') and cytology.' The two sampling methods explored included the Non-GYN Thin Prep'3 and Oragene''DNA Saliva containers.' Analytic and sampling methods and biological samples were tested in various combinations and compared to the gold standard (biopsy tissue): 1) histology for clinical diagnosis, 2) DNA analysis for HR HPV status, and 3) p16 immunohistochemistry (IHC) staining (a biomarker of HPV infection) (Please refer to Table 1).'' '' Results: The sensitivities for the Oragene-Saliva-CervistaHR, ThinPrep-Saliva-CervistaHR, ThinPrep-Scraping-CervistaHR, and ThinPrep-Scraping-Cytology were 100%, 50%, 73.68%, and 36.84%, in order, and their respective specificities were 23.81%, 66.67%, 80.95%, and 71.43%.' There were no statistically significant differences between their performance when testing oropharyngeal and oral cavity lesions (p > 0.05). Conclusion: The high sensitivity (100%) and low specificity (23.81) of Oragene-Saliva-CervistaHR shows that it has a tendency to produce a large number of false positive results.' Since biopsy diagnosis is both expensive and invasive, a test like the ThinPrep-Scraping-CervistaHR with a more balanced sensitivity (73.68%) and specificity (80.95%) is preferred.' Of the four combinations tested, we recommend further investigation of the ThinPrep-Scraping-CervistaHR test.' If proven to be effective, this mildly invasive, readily available, and cost effective method can promote early detection and improve prognosis for the new generation of OPSCC patients. TABLE 1.' METHODS'' Sexual History & Social'' ' Behavior Questionnaire' ' Demographic & Descriptives ''' Saliva, Exfoliated Cells ' and Biopsy Tissue ' 1.' Gold Standard '' Biopsy tissue Histology:' Routine Evaluation & DiagnosisDNA Analysis for HR HPV Statusp16 IHC Staining for HPV Detection' 2.' Combinations (Biologic Sample, Collection Container, and Assay HPV Positive & Negative Saliva and Exfoliated Cells Oragene'-DNA/Saliva Container AND CytologyOragene'-DNA/Saliva Container AND Hologic Cervista' HR HPV Test (Third Wave Invader Chemistry-DNA')Non-GYN ThinPrep' Liquid Based Container/Saliva AND CytologyNon-GYN ThinPrep' Liquid Based Container /Saliva AND Hologic Cervista' HR HPV Test (Third Wave Invader Chemistry-DNA')en
dc.subjectHPV-Related Oropharyngeal Canceren
dc.subjectHuman Pepillomavirusen
dc.subjectScreeningen
dc.date.available2016-03-17T12:56:28Zen
dc.date.issued2016-03-17-
dc.date.issued2016-03-17en
dc.date.accessioned2016-03-17T12:56:28Zen
dc.conference.date2015en
dc.conference.name26th International Nursing Research Congressen
dc.conference.hostSigma Theta Tau International, the Honor Society of Nursingen
dc.conference.locationSan Juan, Puerto Ricoen
dc.descriptionResearch Congress 2015 Theme: Question Locally, Engage Regionally, Apply Globally. Held at the Puerto Rico Convention Center.en
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.